Lexaria Bioscience Corp. Achieves Milestone with 50 Granted Patents Worldwide

Lexaria Bioscience Corp. has announced the receipt of two new international patents, bringing its total worldwide patent portfolio to 50. This achievement underscores the company's commitment to broadening its intellectual property protection and enhancing its drug delivery platforms. The new patents include one in Australia for the treatment of epilepsy and another in Japan for the sublingual delivery of nicotine, both utilizing Lexaria's DehydraTECH™ technology.

The epilepsy treatment patent expands Lexaria's protection outside the USA, where it already holds six patents, and is set to expire in 2044. The nicotine delivery patent in Japan complements existing patents in the USA and Canada, with an expiration date in 2043. These developments come at a time when the epilepsy drug market is projected to grow significantly, and the nicotine pouch market is expected to reach substantial revenues by 2030.

Rich Christopher, CEO of Lexaria, highlighted the strategic importance of these patents in increasing the likelihood of commercial deals within the pharmaceutical industry and building long-term value for stakeholders. The company's DehydraTECH™ technology has demonstrated potential in improving drug absorption and delivery, particularly in oral formats, positioning Lexaria as a key player in the evolving drug delivery landscape.